EXTENDED REPORT

Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women

S Kluzek,1,2 M T Sanchez-Santos,1,2 K M Leyland,1,2 A Judge,1,3 T D Spector,4 D Hart,4 C Cooper,1,3 J Newton,1,2 N K Arden1,2,3

ABSTRACT

Objective To assess whether joint pain or radiographic osteoarthritis (ROA) of the knee and hand is associated with all-cause and disease-specific mortality in middle-aged women.

Methods Four subgroups from the prospective community-based Chingford Cohort Study were identified based on presence/absence of pain and ROA at baseline: (Pain−/ROA−; Pain+/ROA−; Pain−/ROA+; Pain+/ROA +). Pain was defined as side-specific pain in the preceding month, while side-specific ROA was defined as Kellgren-Lawrence grade ≥2. All-cause, cardiovascular disease (CVD) and cancer-related mortality over the 23-year follow-up was based on information collected by the Office for National Statistics. Associations between subgroups and all-cause/cancer-specific mortality were assessed using Cox regression, adjusting for age, body mass index, typical cardiovascular risk factors, occupation, past physical activity, existing CVD disease, glucose levels and medication use.

Results 821 and 808 women were included for knee and hand analyses, respectively. Compared with the knee Pain−/ROA− group, the Pain+/ROA− group had an increased risk of CVD-specific mortality (HR 2.93 (95% CI 1.47 to 5.85)), while the knee knee Pain−/ROA+ group had an increased HR of 1.97 (95% CI 1.23 to 3.17) for all-cause and 3.57 (95% CI 1.53 to 8.34) for CVD-specific mortality. We found no association between hand OA and mortality.

Conclusion We found a significantly increased risk of all-cause and CVD-specific mortality in women experiencing knee pain with or without ROA but not ROA alone. No relationship was found between hand OA and mortality risk. This suggests that knee pain, more than structural changes of OA is the main driver of excess mortality in patients with OA.

INTRODUCTION

Osteoarthritis (OA) is the most common form of arthritis and a significant contributor of musculoskeletal disability burden in the developed world.1 In the population aged above 55 years, one in four women and one in six men report knee pain.2 The lifetime risk of receiving a total knee replacement at age 50 is 8.1% for men and 10.8% for women.3 The prevalence of symptomatic hand OA is 8.2% and 15.9% in men and women, respectively.4 There is growing evidence that low-grade systemic inflammation, linked with adipose tissue, is associated with joint pain,5–7 incidence of radiographic changes,6 9 development of cardiovascular disease (CVD)10–12 and also have a role in the cancer pathogenesis.13 Compared with individuals with no OA, participants with total joint replacements have a 26% increased risk of CVD.14 Furthermore, a younger middle-aged population with OA have a fivefold increased prevalence of metabolic syndrome.15 16

The strongest evidence of a relationship between OA and mortality comes from an observational study where patients with symptomatic radiographic KOA and/or hip OA were selected and found to be at increased mortality risk compared with general population.17 A more recent study demonstrates a borderline significant association between excess mortality and symptomatic (but not radiographic) KOA alone.18 19 Hand OA was associated with a risk of premature CVD death in the Finnish population aged 30 years and over.19–21 In contrast, a more recent publication demonstrates no association with an excess mortality and hand OA, despite increased risk of coronary heart disease events in a population with symptomatic hand OA.22 It is currently unclear whether symptomatic or radiographic only OA is associated with excess mortality. The aim of our study was to examine the relationship between KOA and hand OA and the risk of mortality in a longitudinal community-based cohort with 23 years of follow-up. Participants were divided into four subgroups based on presence or absence of pain and radiographic osteoarthritis (ROA).

METHODS

Study population

Characteristics of the Chingford study have been described in detail previously.23 Briefly, in Chingford, North London, UK, all women aged 45–64 years from the register of a large general practice were contacted in 1988–1989 and asked to participate in a population-based study to evaluate risk factors for osteoporosis and OA. Among 1353 women contacted, 1003 (78% response rate)
attended the baseline visit and have since been examined annually. This cohort has been shown to be representative of women in England.23

Inclusion criteria
We included 821 women for knee and 808 for hand analyses with available data on both pain and radiographic KOA or hand OA. Women with the following diseases (n=43) at baseline or any point of follow-up were excluded from analysis: rheumatoid arthritis, psoriatic arthritis, gout, Paget’s disease, polio, cerebral palsy and chronic inflammatory demyelinating neuropathy. Two participants were excluded due to lack of time-to-death data. Further, 137 women for knee and 150 for hand analyses were excluded due to lack of pain and/or radiographic data at baseline (figure 1). Characteristics of the participants without baseline radiographic or pain data were similar with those included for analyses.

Assessment of mortality
The outcomes of interest were all-cause and cause-specific mortality from CVD and cancer, based on available data up to August 2014. The Health and Social Care Information Centre provided detailed mortality information on the Chingford cohort based on the information collected by the Office for National Statistics from civil registration records. The cause of death was based on the information from death certificates. For the cause-specific mortality, we reviewed all CVD and cancer-related deaths data from death certificates. In seven cases of cardiovascular mortality, the cause of death was changed to cancer-related mortality, if the direct cause of death was a complication of cancer or its treatment. The cumulative number of deaths over the 23 years (median 21.7 years (IQR: 21.2–22.3)) of follow-up was 223 women (22.2%) out of the total sample of 1003 women. CVD mortality accounted for 29% (n=64), cancer for 45% (n=100) and other diseases for 26% (n=59) of all-cause mortality. Time-to-event was assessed from year 3 until death, or the end of the follow-up (15 August 2014).

Assessment of joint-specific OA and pain
A physical examination at baseline (year 1) was performed to assess anteroposterior (AP) radiographs of the hands and weight-bearing AP radiographs of the knees. The protocols for radiographic grading and reproducibility for both KOA and hand OA and for this study have been previously reported.24–27

Women were classified as having radiographic KOA if they had a Kellgren–Lawrence (K/L) OA grade of 2 or more in at least one knee at baseline. Hand radiographs were also graded for OA. Summary scores of distal interphalangeal, proximal interphalangeal and first carpometacarpal joints were defined as the number of joints with K/L grade ≥ 2, while radiographic hand OA in any hand joint was defined as positive if the K/L score in at least one joint was ≥ 2.

Knee and hand pain was assessed at year 3 as part of a self-administered questionnaire.28 Women were asked if they had

---

Figure 1 A flow diagram of participants included and excluded for each analysis. *Rheumatoid arthritis, psoriatic arthritis, gout, Paget’s disease, polio, cerebral palsy and chronic inflammatory demyelinating neuropathy.
experienced any knee/hand pain in the past month and the number of days this had occurred. Knee/hand pain was classified as positive for either knee/hand if ‘yes’ and ‘more than 0 days’ were reported.

Joint-specific OA and pain was classified into four subgroups based on presence and absence of pain and ROA:
2. ROA (Pain−/ROA+).
3. Pain only (Pain+/ROA−).
4. Painful ROA (Pain+/ROA+: joint(s) with ROA and pain in the same side).

Women with ROA only in one side and pain only in the contralateral side were classified as having ROA+/Pain− only.

Potential confounders
We assessed information on potential confounders at year 3. Sociodemographic covariates included age and occupation (‘Manual’ vs ‘Non-manual’). Health-related behaviours were physical activity (PA) at age 30 and smoking. PA at age 30 was assessed by the following question: ‘Were you a physically active person at age 30?’ Smokers were classified as never smoked/ex-smoker or currently smoking. Current and past CVD disease was ascertained by asking the women if they had any CVD disease. We included all risk factors for heart disease that are part of the Framingham Heart Study Risk Assessment.29 The biological factors included were body mass index (BMI), systolic blood pressure (BP), total and high-density lipoprotein (HDL) cholesterol and glucose. BMI was calculated at baseline and divided into two groups: ‘non-obese’ (BMI <30 kg/m2) and ‘obese’ (BMI ≥30 kg/m2). Total and HDL cholesterol and glucose were measured by fasting serum samples taken.30 For the analysis, systolic BP total and HDL cholesterol and glucose were treated as continuous variables. BP medication, non-steroidal anti-inflammatory drugs (NSAIDs) and hormone replacement therapy (HRT) use were coded as dichotomous variables with a value of 1 if the women reported taking the medication and 0 otherwise.

Statistical analysis
All analyses were conducted using Stata V13 statistical software (StataCorp, College Station, Texas, USA) and took place separately for knee and hand. Multiple imputation using chained equations was used to investigate the impact of missing potential confounders, while 100 imputed datasets were generated using all potential confounders (including all-cause mortality and log-transformed survival time) and estimated parameters were combined using Rubin’s rules. Kaplan–Meier survival curves for all-cause mortality in joint-specific OA and pain subgroups were estimated.

The association between joint-specific OA and pain subgroups (knee and hand) and all-cause and cause-specific mortality was assessed using Cox proportional hazards regression models to estimate HRs and 95% CIs. Three models were used to assess this association:
Model (1) was age-adjusted.
Model (2) added risk factors from Framingham Risk Score (smoking, total cholesterol, HDL-cholesterol, systolic BP and BP medication).
Model (3) added the remaining potential confounders (occupation, HRT use, past PA, BMI, current/previous CVD disease, non-acetylsalicylic acid (ASA) NSAIDs and glucose levels).

In the analyses of specific cause of death, deaths attributed to other causes were treated as censored at the time of death. Proportional hazards assumption was examined by Schoenfeld residuals. There was no evidence showing that the hazards were not proportional over the follow-up period studied.

Four sensitivity analyses were conducted. First, we excluded women who underwent joint-specific surgery at any point during follow-up. Second, all deaths occurring during the first 12 months of follow-up were excluded. Third, with a radiographic hand OA defined as positive if the K/L score in at least two joints was ≥2. Forth, with available crude measures of PA, this was assessed by the following question, ‘How many times per week do you engage in activity that makes you sweat?’

RESULTS
From 1993 to 2014 (median follow-up of 21.7 years: range: 21.2–22.3), 166 and 163 deaths (~20%) were confirmed by death certificate among the KOA and hand OA and pain study sample, respectively. Potential confounders according to KOA and hand OA and pain categories are presented in tables 1 and 2, respectively. Compared with women without OA (Pain−/ROA−), women with ROA (Pain+ and Pain−) were older and had higher systolic BP levels (tables 1 and 2). Women with painful knee (ROA+ or ROA−) were more likely to use non-ASA NSAIDs (table 1). Women with knee or hand pain (Pain+/ROA−) were also more likely to be using HRT medication, compared with the other subgroups.

Kaplan–Meier survival curves for all-cause mortality according to KOA and pain (figure 2A) and hand OA and pain categories (figure 2B) are presented in figure 2. Women with painful knee/hand ROA had a greater risk of all-cause mortality compared with women with neither knee/hand pain nor ROA (log-rank test p≤0.001).

Results from Cox proportional hazards model estimating the mortality risk according to KOA and hand OA and pain categories are shown in tables 3 and 4. In the age-adjusted model, women with knee pain and no ROA had a 49% increased risk of dying from all-cause mortality, compared with those with neither knee pain nor ROA (HR 1.49 95% CI 1.04 to 2.14; p=0.029). The mortality risk was stronger among women with painful knee ROA, reaching a 97% increase in mortality risk in an age-adjusted model (HR 1.97 95% CI 1.23 to 3.17; p=0.005) (Model 1; table 3).

After adjustment for the factors from Framingham Risk Score Factors (Model 2; table 3), the HRs increased slightly for painful knee subgroups (ROA+, ROA−) (1.55 (95% CI 1.07 to 2.22) and 2.06 (95% CI 1.27 to 3.33), respectively) (Model 2; table 3). The relationship remained unchanged even after further adjusting for all other covariates (Model 3; table 3). In contrast, knee ROA alone was not associated with mortality in any of the three models.

The magnitude of association between knee pain subgroups (Pain+/ROA− and Pain+/ROA+) and mortality was the strongest for CVD-specific mortality in all models. Compared with women with neither knee pain nor ROA, the HR associated with knee pain only (Pain+/ROA−) was 3.25 (95% CI 1.64 to 6.43) and with painful knee ROA (Pain+/ROA+) was 4.19 (95% CI 1.87 to 9.40), after adjustment for Framingham Risk Score factors (Model 2; table 3). Further inclusion of all other covariates produced an almost negligible reduction in the HR for CVD-specific mortality (Model 3; table 3). No statistically significant associations were found for cancer-specific mortality.

Additionally, there were no associations between hand pain, with or without ROA, and all-cause or cause-specific mortality after adjustment for other covariates (table 4).

No substantial differences in the results were observed when women who died during the first 12 months of follow-up...
(n=2), or when women who underwent knee replacement (for knee analysis) during the follow-up (n=29) were excluded (data not shown).

**DISCUSSION**

In this prospective community-based study of middle-aged women, we found a significant association between knee pain, with or without ROA, and an increased risk of all-cause and CVD-specific mortality. We found no association between knee ROA only (Pain−/ROA+) and decreased survival, although subjects with symptomatic ROA (Pain+/ROA+) had the highest risk of both all-cause and CVD-specific mortality. No relationship was found between hand OA and mortality risk.

There are conflicting results between observational studies on the impact of KOA and hand OA on early mortality. Cerhan et al found that ROA of hands, knees and the cervical spine was associated with decreased survival of middle-aged women who worked in the radium dial-painting industry, when compared with participants without ROA. A systematic review on this subject found moderate evidence of increased mortality among participants with OA compared with the general population. Two studies based on the Finnish national health survey reported modest association between advanced radiographic hand OA and risk of early mortality. However, Haugen et al have not confirmed those findings in the Framingham Study.

Nüesch et al used a large selected population-based sample of men and women with symptomatic radiographic knee and/or hip OA and compared age and sex standardised mortality ratios after a median of 14 years’ follow-up. They reported a significant excess in all-cause, CVD-related and dementia-related mortality. Liu et al found that participants from two different cohorts of patients consulting health professionals for their OA were not at higher risk of death than the general population (mean follow-up time below 7 years). Hawker et al showed that increased walking disability, use of walking aids and poor baseline function are associated with excess all-cause mortality in individuals with hip OA and KOA symptoms.

The main limitations of the previous studies include:
- Relatively short follow-up,
- Selection towards participants with symptomatic radiographic OA,
- Comparison with controls from population mortality registers or participants with no ROA, with no study using a comparison group without pain and ROA.

This paper confirms strong independent association between painful knee (but not hand) OA and excess mortality. This relationship is independent from the majority of known CVD risk factors and not attenuated by non-ASA NSAIDs use, which corresponds with previous findings.
We have found that any self-reported knee pain in the past month, with or without radiographic KOA changes, but not symptomatic hand OA or radiographic KOA alone, is a significant predictor of early CVD mortality. There are number of plausible explanations for our findings, which are not mutually exclusive. The most biologically plausible mechanism for...
Women with KOA have higher levels of markers associated with their symptoms and perceive PA to lead to the inflammatory response and inactivity linked with painful KOA might accelerate metabolic dysregulation. The pain in KOA fluctuates and people commonly limit the activities associated with their symptoms and perceive PA to lead to the disease progression. Despite, clear evidence suggesting that PA improves pain, quality of life and minimises disability in individuals with KOA, we lack evidence supporting that any interventions in patients with KOA improve PA levels or cardiovascular fitness in the longer term.

To our knowledge, this is the first longitudinal prospective community-based cohort with over two decades follow-up.

### Table 3 Number of deaths (n) and HR (95% CI) of all-cause and disease-specific mortality by knee OA categories

<table>
<thead>
<tr>
<th>Outcome Knee OA status</th>
<th>No. of deaths (%)</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
<td>p Value</td>
<td>HR</td>
</tr>
<tr>
<td>All-causes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neither ROA nor pain</td>
<td>84 (16.0)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>ROA only</td>
<td>14 (21.9)</td>
<td>0.95</td>
<td>0.54 to 1.69</td>
<td>0.865</td>
</tr>
<tr>
<td>Pain only</td>
<td>46 (26.1)</td>
<td>1.49</td>
<td>1.04 to 2.14</td>
<td>0.029</td>
</tr>
<tr>
<td>Painful ROA</td>
<td>22 (38.6)</td>
<td>1.97</td>
<td>1.23 to 3.17</td>
<td>0.005</td>
</tr>
<tr>
<td>CVD disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neither ROA nor pain</td>
<td>17 (3.2)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>ROA only</td>
<td>4 (6.3)</td>
<td>1.14</td>
<td>0.38 to 3.43</td>
<td>0.811</td>
</tr>
<tr>
<td>Pain only</td>
<td>18 (10.2)</td>
<td>2.78</td>
<td>1.43 to 5.41</td>
<td>0.003</td>
</tr>
<tr>
<td>Painful ROA</td>
<td>10 (17.5)</td>
<td>3.98</td>
<td>1.81 to 8.76</td>
<td>0.001</td>
</tr>
<tr>
<td>Cancer disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neither ROA nor pain</td>
<td>44 (8.4)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>ROA only</td>
<td>7 (10.9)</td>
<td>1.08</td>
<td>0.48 to 2.41</td>
<td>0.860</td>
</tr>
<tr>
<td>Pain only</td>
<td>19 (10.8)</td>
<td>1.23</td>
<td>0.72 to 2.12</td>
<td>0.444</td>
</tr>
<tr>
<td>Painful ROA</td>
<td>6 (10.5)</td>
<td>1.17</td>
<td>0.49 to 2.78</td>
<td>0.719</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age.
Model 2: Model 1+Smoking, total cholesterol, HDL-cholesterol, systolic BP and BP medication (Framingham Risk Score Factors).
Model 3: Model 2+occupation, BMI, HRT use, past physical activity, current/previous CVD disease, non-ASA NSAIDs and glucose levels.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL, High-density lipoprotein; HRT, hormone replacement therapy; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; ROA, radiographic osteoarthritis.

### Table 4 Number of deaths (n) and HR (95% CI) of all-cause and disease-specific mortality by hand OA categories

<table>
<thead>
<tr>
<th>Outcome Hand OA status</th>
<th>No. of deaths (%)</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
<td>p Value</td>
<td>HR</td>
</tr>
<tr>
<td>All-causes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neither ROA nor pain</td>
<td>66 (15.9)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>ROA only</td>
<td>43 (25.9)</td>
<td>0.94</td>
<td>0.62 to 1.41</td>
<td>0.754</td>
</tr>
<tr>
<td>Pain only</td>
<td>23 (18.1)</td>
<td>1.02</td>
<td>0.64 to 1.65</td>
<td>0.920</td>
</tr>
<tr>
<td>Painful ROA</td>
<td>31 (31.3)</td>
<td>1.13</td>
<td>0.72 to 1.77</td>
<td>0.591</td>
</tr>
<tr>
<td>CVD disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neither ROA nor pain</td>
<td>18 (4.3)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>ROA only</td>
<td>10 (6.0)</td>
<td>0.60</td>
<td>0.27 to 1.34</td>
<td>0.212</td>
</tr>
<tr>
<td>Pain only</td>
<td>10 (7.9)</td>
<td>1.54</td>
<td>0.71 to 3.33</td>
<td>0.276</td>
</tr>
<tr>
<td>Painful ROA</td>
<td>8 (8.1)</td>
<td>0.80</td>
<td>0.34 to 1.91</td>
<td>0.620</td>
</tr>
<tr>
<td>Cancer disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neither ROA nor pain</td>
<td>33 (7.9)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td>ROA only</td>
<td>22 (13.3)</td>
<td>1.28</td>
<td>0.71 to 2.29</td>
<td>0.407</td>
</tr>
<tr>
<td>Pain only</td>
<td>9 (7.1)</td>
<td>0.85</td>
<td>0.41 to 1.78</td>
<td>0.665</td>
</tr>
<tr>
<td>Painful ROA</td>
<td>12 (12.1)</td>
<td>1.17</td>
<td>0.58 to 2.35</td>
<td>0.662</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age.
Model 2: Model 1+Smoking, total cholesterol, HDL-cholesterol, systolic BP and BP medication (Framingham Risk Score Factors).
Model 3: Model 2+occupation, BMI, HRT use, past physical activity, current/previous CVD disease, non-ASA NSAIDs and glucose levels.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL, High-density lipoprotein; HRT, hormone replacement therapy; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; ROA, radiographic osteoarthritis.
looking at the effect of knee and hand pain with and without ROA on all-cause and disease-specific mortality in middle-aged women. Participants’ selection to enter this study was not based on symptomatology or radiographic features. The comparison group is part of the same population and has no radiographic disease at baseline or side-specific pain. With comprehensive baseline data, we adjusted our analysis for potentially important multiple confounders, including all risk factors from the Framingham Heart Study. We performed a sensitivity analysis with a radiographic hand OA defined as the K/L score ≥2 in at least two joints, and this did not attenuate our findings.

Some potential limitations are worth mentioning. Findings of this study are limited to middle-aged and predominantly Caucasian women. In multivariable analysis of groups, we used baseline values of covariates, but those values may change over time and have time-dependent effects on OA and mortality outcomes that we would not be able to comment on in this analysis. This analysis is likely to underestimate the absolute risk of the exposure groups due to the fact that participants from the control group (ROA−/Pain−) remain in the original group even if they develop pain and/or ROA over time. In this study all exposure categories have this immortal time period. The other important limitation of this study is the fact that radiographs of the hands and knees were taken 3 years before knee and hand pain assessment. To mitigate against this, outcomes were measure from year 3 onwards. The PA and function is another potential residual confounding. We performed a sensitivity analysis using an available crude measures of PA that, when adjusted for, did not attenuate the findings.

In conclusion, knee pain with or without ROA in middle-aged women is associated with an increased all-cause and CVD mortality only. The highest risk was found in subjects with both pain and ROA, with no association found with ROA alone. In addition, there was no association between hand pain, with or without ROA, and all-cause and specific-cause mortality. The link behind this relationship is not completely understood. Further research analysing the longitudinal differences in the groups’ characteristics associated with CVD mortality is required to identify potential underlying mechanisms. Additional studies of men-only or mixed gender cohorts are needed to confirm generalisability of these findings.

**REFERENCES**

Clinical and epidemiological research


36 Gonzalez EB. Nonsteroidal anti-inflammatory drugs did not increase risk for all-cause mortality in osteoarthritis. ACP J Club 2007;146:77.


Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women

S Kluzek, M T Sanchez-Santos, K M Leyland, A Judge, T D Spector, D Hart, C Cooper, J Newton and N K Arden

Ann Rheum Dis published online November 5, 2015

Updated information and services can be found at: http://ard.bmj.com/content/early/2015/11/05/annrheumdis-2015-208056

References

This article cites 48 articles, 18 of which you can access for free at: http://ard.bmj.com/content/early/2015/11/05/annrheumdis-2015-208056#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Epidemiology (1338)
- Pain (neurology) (864)
- Degenerative joint disease (4536)
- Musculoskeletal syndromes (4841)
- Osteoarthritis (919)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/